{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:54:18Z","timestamp":1787838858496,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Lacosamide (LCM) is a new antiepileptic drug (AED). The purpose of the study was to investigate the effects of LCM dose, body weight, height, sex, age, and concomitant AEDs on LCM trough serum concentrations (at a steady state) in patients with epilepsy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total number of 3154 blood samples of 973 consecutive patients of the Mara Hospital (Bethel Epilepsy Centre) were evaluated. Generalized estimating equation (GEE) models were used for statistical analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>GEE analyses showed that LCM trough serum concentrations were significantly correlated with the body weight\u2013normalized LCM dose (range: 0.44\u201325.7 mg\/kg; 45\u20131050 mg) and significantly dependent on comedication and age. Compared with adults (18\u201360 years), the LCM trough serum concentrations of children aged 6\u201312 years and children younger than 6 years were significantly lower (\u221221% to \u221238%, respectively) and those of elderly patients (&gt;60 years) were significantly higher (+20%). Sex had no significant influence. Carbamazepine, phenytoin, primidone, phenobarbital, and methsuximide decreased LCM trough serum concentrations significantly by 30%, 32%, 34%, 39%, and 41%, respectively, whereas other AEDs (eg, oxcarbazepine, eslicarbazepine acetate, valproate) had no significant or only a minor impact (zonisamide) on LCM trough concentrations. In children, the effect of enzyme-inducing AEDs was more marked. Of note, the number of blood samples (n = 151) of patients younger than 12 (n = 78) was comparatively low. Alternative GEE models confirmed the effect of comedication, whereas the effect of age, especially in children, depended on adjustment of LCM dosage to body weight, body surface area, or approximated volume of distribution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In accordance with previous therapeutic drug monitoring studies, our results confirmed that enzyme inducers reduce the LCM trough serum concentrations by 30%\u201340%. In children, the effects of comedication are more pronounced but should be confirmed by further studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000538","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T22:18:38Z","timestamp":1533248318000},"page":"620-627","source":"Crossref","is-referenced-by-count":26,"title":["Influence of Dose and Antiepileptic Comedication on Lacosamide Serum Concentrations in Patients With Epilepsy of Different Ages"],"prefix":"10.1097","volume":"40","author":[{"given":"Theodor W.","family":"May","sequence":"first","affiliation":[{"name":"Society for Epilepsy Research; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Helmer","sequence":"additional","affiliation":[{"name":"Society for Epilepsy Research; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Bien","sequence":"additional","affiliation":[{"name":"Bethel Epilepsy Center, Mara Hospital, Bielefeld, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brandt","sequence":"additional","affiliation":[{"name":"Bethel Epilepsy Center, Mara Hospital, Bielefeld, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":"Lacosamide: a review of preclinical properties","volume":"13","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.12513","article-title":"Advances in epilepsy treatment: lacosamide pharmacokinetic profile","volume":"1329","author":"Cawello","year":"2014","journal-title":"Ann N Y Acad Sci."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40262-015-0276-0","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lacosamide","volume":"54","author":"Cawello","year":"2015","journal-title":"Clinic Pharmacokinet."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eplepsyres.2011.03.019","article-title":"Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions\u2014first clinical experience","volume":"95","author":"Sattler","year":"2011","journal-title":"Epilepsy Res."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ajcn\/33.1.27","article-title":"Total body water volumes for adult males and females estimated from simple anthropometric measurements","volume":"33","author":"Watson","year":"1980","journal-title":"Am J Clin Nutr."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/adc.2004.067538","article-title":"Prediction of total body water in infants and children","volume":"90","author":"Wells","year":"2005","journal-title":"Arch Dis Child."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/epi.13022","article-title":"Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy","volume":"56","author":"May","year":"2015","journal-title":"Epilepsia."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1177\/0091270011426875","article-title":"No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers","volume":"52","author":"Cawello","year":"2012","journal-title":"J Clin Pharmacol."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0091270009347675","article-title":"No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers","volume":"50","author":"Cawello","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FTD.0000000000000051","article-title":"Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs","volume":"36","author":"Markoula","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/FTD.0b013e318290eacc","article-title":"Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs","volume":"35","author":"Contin","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s11064-017-2234-8","article-title":"Therapeutic drug monitoring of lacosamide in Norway: focus on pharmacokinetic variability, efficacy and tolerability","volume":"42","author":"Svendsen","year":"2017","journal-title":"Neurochem Res."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1586\/ecp.12.10","article-title":"Methodologies used to identify and characterize interactions among antiepileptic drugs","volume":"5","author":"Johannessen Landmark","year":"2012","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1528-1157.2000.tb00218.x","article-title":"Methsuximide lowers lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction","volume":"41","author":"Besag","year":"2000","journal-title":"Epilepsia."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","article-title":"Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study","volume":"21","author":"May","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","article-title":"Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication","volume":"24","author":"May","year":"2002","journal-title":"Ther Drug Monit."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00007691-200312000-00007","article-title":"Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication","volume":"25","author":"May","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FTD.0b013e31820fa9ad","article-title":"Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication","volume":"33","author":"May","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FTD.0b013e31825dc4a6","article-title":"Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication","volume":"34","author":"May","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika."},{"key":"R26-20230814","first-page":"313","article-title":"Pharmacokinetics of the new antiepileptic drug SPM927 in human subjects with different age and gender [abstract 2.361]","volume":"45","author":"Schiltmeyer","year":"2010","journal-title":"Epilepsia."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40261-015-0277-7","article-title":"Effect of age and sex on lacosamide pharmacokinetics in healthy adult subjects and adults with focal epilepsy","volume":"35","author":"Schaefer","year":"2015","journal-title":"Clin Drug Investig."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurother."},{"key":"R30-20230814","first-page":"161","article-title":"Therapeutic drug monitoring of newer antiepileptic drugs","volume":"35","author":"Brandt","year":"2011","journal-title":"J Lab Med."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201810000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:22:31Z","timestamp":1692051751000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201810000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000538","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}